Zydus Lifesciences Q4 FY26 Results: PAT Rs 1,272.5 Cr

Zydus Lifesciences Q4 FY26 results were declared on May 19, 2026. Zydus Lifesciences reported PAT of Rs 1,272.5 crore up 8.7% YoY from Rs 1,170.9 crore in Q4 FY25, on revenue of Rs 7,587 crore up 16.2% YoY. Zydus Lifesciences is a Pharmaceuticals company listed on Indian stock exchanges. This article covers the complete Zydus Lifesciences Q4 FY26 financial highlights, key performance factors, and FY27 outlook for investors tracking Zydus Lifesciences.

Click Here – Get Free Investment Predictions

Zydus Lifesciences Q4 FY26 Financial Highlights

Note: Also approved Rs 1,100 crore share buyback. Buyback record date May 29 2026. EBITDA Rs 2,554 crore (+20.2% YoY).

Zydus Lifesciences Q4 FY26 Performance Analysis

The Zydus Lifesciences Q4 FY26 results reflect Zydus Lifesciences’s operational performance during the January to March 2026 quarter. The company operates in the Pharmaceuticals space, a sector supported by India’s strong GDP growth and domestic demand. The Q4 FY26 results demonstrate continued business execution and operational resilience.

Screen the best stocks on the Univest Screener.

Investors tracking Zydus Lifesciences Q4 FY26 will focus on FY27 revenue guidance, margin trajectory, and management’s capital allocation commentary. Track Zydus Lifesciences on the Univest Screener for live fundamentals and real-time updates.

Key Business Factors for Zydus Lifesciences Q4 FY26

Revenue and Operational Performance

Zydus Lifesciences Q4 FY26 performance reflects the January to March 2026 quarter, historically the year-end quarter with strong order execution and seasonality effects. India’s macroeconomic environment with GDP growth above 6.5% provided a constructive backdrop for the Pharmaceuticals sector during this period.

Profitability and Margin Trends

the company PAT of Rs 1,272.5 crore up 8.7% YoY from Rs 1,170.9 crore in Q4 FY25. Sustaining profitability and improving operating margins will be key watchpoints for FY27 performance.

India Economic Context for Zydus Lifesciences

The January to March 2026 quarter saw strong domestic consumption, fiscal year-end capital expenditure cycles, and government infrastructure spending. The Reserve Bank of India’s supportive monetary stance and India’s resilient growth trajectory provided a stable environment for listed companies across sectors. For Zydus Lifesciences, operating in the Pharmaceuticals space, this macro backdrop supported demand conditions during the quarter.

FY27 Outlook and Growth Drivers

Following the listed company results, management commentary on FY27 revenue guidance, capex plans, and order pipeline will be the primary catalysts for investor sentiment. The Pharmaceuticals sector continues to benefit from India’s structural growth, rising domestic consumption, and government policy support.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the group

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.